Back to top
more

Insmed (INSM)

(Delayed Data from NSDQ)

$26.08 USD

26.08
1,194,062

+0.13 (0.50%)

Updated May 7, 2024 04:00 PM ET

After-Market: $26.07 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (74 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for INSM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insmed, Inc. [INSM]

Reports for Purchase

Showing records 61 - 80 ( 112 total )

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 61

10/19/2015

Daily Note

Pages: 4

Update from FDA Patient-Focused NTM Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 62

10/06/2015

Company Report

Pages: 8

NTM Update from ERS 2015; Reit Buy Rating and Raising PT to $35

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 63

08/07/2015

Company Report

Pages: 7

2Q15 Update: Fortune Favors the Prepared

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 64

05/21/2015

Company Report

Pages: 7

Arikayce Culture Conversion, Revisited

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 65

03/25/2015

Company Report

Pages: 7

Arikayce Very Well Positioned for Success as We Grow Increasingly More Comfortable with Pipeline; Reit Buy and $30 PT

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 66

11/21/2014

Daily Note

Pages: 4

Takeaways from the NTM Symposium in NYC

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 67

11/07/2014

Company Report

Pages: 6

Arikayce to Remain on Orphan Course to US Market

Provider: H.C. WAINWRIGHT & CO., INC.

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 68

05/20/2014

Company Report

Pages: 4

Dropping Coverage Due to Analyst Departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 69

05/09/2014

Company Report

Pages: 8

Transitioning Coverage, Q1:14 Results, Full Data from the Phase II Target Study Anticipated Soon

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 70

04/11/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of April 14

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 71

03/30/2014

Daily Note

Pages: 4

Update Following Our Infectious Disease Physician Checks - Clinical Improvement Should Accompany a Real Decrease in Bacterial Load in the Lungs

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 72

03/26/2014

Company Report

Pages: 8

ARIKAYCE Phase II Study Generates Potential Positive Culture Conversion Efficacy Signal

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 73

03/24/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 74

03/24/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 75

03/16/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 76

02/28/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE: The Week Ahead in Life Sciences - Upcoming Events for the Week of March 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 77

02/21/2014

Daily Note

Pages: 4

Limitations in the Recently Presented Cystic Fibrosis Extension Study Dataset

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 78

02/21/2014

Daily Note

Pages: 4

Limitations in the Recently Presented Cystic Fibrosis Extension Study Dataset

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 79

02/14/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 17

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Insmed, Inc.

Industry: Medical - Biomedical and Genetics

Record: 80

02/11/2014

Company Report

Pages: 8

Downgrading to UNDERPERFORM from OUTPERFORM - Adjusting Model to Reflect the Timing Associated with a U.S. Phase III for NTM Approval

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party